Published in AIDS Weekly, May 4th, 1998
Serum from a person with long-term nonprogressive HIV infection is able to recognize a wide variety of HIV isolates from many different viral subtypes.
These antibodies suggest that this individual mounted an immune response to an HIV antigen capable of eliciting cross-clade neutralization - something no current candidate HIV vaccine antigen can do.
"Further analysis ... should provide insight into the required structure of envelope protein in vaccine," said Gerald V. Quinnan of the Uniformed Services University of the Health Sciences, National Institutes of Health,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1998-05-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.